Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels

Molecular Genetics and Metabolism

Volumn 101, Issue 1, 2010, Pages 66-75

  Imaizumi, Satoshi ^a   Grijalva, Victor ^a   Priceman, Saul ^a   Wu, Lily ^a   Su, Feng ^a   Farias Eisner, Robin ^a   Hama, Susan ^a   Navab, Mohamad ^a   Fogelman, Alan M ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Mitogen activated protein kinase phosphatase 1; Monocyte chemoattractant protein 1; Monocytes

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; HYDROXYICOSATETRAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HYPERLIPIDEMIA; MACROPHAGE; MALE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1 DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

MUS;

EID: 77955657490     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.05.009     Document Type: Article

References (46)

1. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8:1235-1242.
2. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
3. Weis M., Schlichting C.L., Engleman E.G., Cooke J.P. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1817-1823.
4. Reddy S.T., Grijalva V., Ng C., Hassan K., Hama S., Mottahedeh R., Wadleigh D.J., Navab M., Fogelman A.M. Identification of genes induced by oxidized phospholipids in human aortic endothelial cells. Vascul. Pharmacol. 2002, 38:211-218.
5. Navab M., Hama S.Y., Reddy S.T., Ng C.J., Van Lenten B.J., Laks H., Fogelman A.M. Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 2002, 13:363-372.
6. Reddy S., Hama S., Grijalva V., Hassan K., Mottahedeh R., Hough G., Wadleigh D.J., Navab M., Fogelman A.M. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells. J. Biol. Chem. 2001, 276:17030-17035.
7. Owens D.M., Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007, 26:3203-3213.
8. Sanchez-Tillo E., Comalada M., Farrera C., Valledor A.F., Lloberas J., Celada A. Macrophage-colony-stimulating factor-induced proliferation and lipopolysaccharide-dependent activation of macrophages requires Raf-1 phosphorylation to induce mitogen kinase phosphatase-1 expression. J. Immunol. 2006, 176:6594-6602.
9. Valledor A.F., Arpa L., Sanchez-Tillo E., Comalada M., Casals C., Xaus J., Caelles C., Lloberas J., Celada A. IFN-{gamma}-mediated inhibition of MAPK phosphatase expression results in prolonged MAPK activity in response to M-CSF and inhibition of proliferation. Blood 2008, 112:3274-3282.
10. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
11. Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., Leenen P.J. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 2004, 172:4410-4417.
12. Varol C., Yona S., Jung S. Origins and tissue-context-dependent fates of blood monocytes. Immunol. Cell Biol. 2009, 87:30-38.
13. Gordon S. Macrophage heterogeneity and tissue lipids. J. Clin. Invest. 2007, 117:89-93.
14. Packard R.R., Maganto-Garcia E., Gotsman I., Tabas I., Libby P., Lichtman A.H. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ. Res. 2008, 103:965-973.
15. Dorfman K., Carrasco D., Gruda M., Ryan C., Lira S.A., Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996, 13:925-931.
16. Reddy S.T., Nguyen J.T., Grijalva V., Hough G., Hama S., Navab M., Fogelman A.M. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1676-1681.
17. Hedrick C.C., Castellani L.W., Warden C.H., Puppione D.L., Lusis A.J. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J. Biol. Chem. 1993, 268:20676-20682.
18. Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 2006, 176:1899-1907.
19. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 2000, 275:17527-17535.
20. Tangirala R.K., Rubin E.M., Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid. Res. 1995, 36:2320-2328.
21. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid. Res. 2000, 41:1481-1494.
22. Li L., Chen S.F., Liu Y. MAP kinase phosphatase-1, a critical negative regulator of the innate immune response. Int. J. Clin. Exp. Med. 2009, 2:48-67.
23. Swirski F.K., Libby P., Aikawa E., Alcaide P., Luscinskas F.W., Weissleder R., Pittet M.J. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 2007, 117:195-205.
24. Shaposhnik Z., Wang X., Weinstein M., Bennett B.J., Lusis A.J. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2007, 27:621-627.
25. Wen Y., Gu J., Vandenhoff G.E., Liu X., Nadler J.L. Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1933-H1938.
26. Silva A.R., Pacheco P., Vieira-de-Abreu A., Maya-Monteiro C.M., D'Alegria B., Magalhaes K.G., de Assis E.F., Bandeira-Melo C., Castro-Faria-Neto H.C., Bozza P.T. Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon. Biochim. Biophys. Acta 2009, 1791:1066-1075.
27. Shen J., Chandrasekharan U.M., Ashraf M.Z., Long E., Morton R.E., Liu Y., Smith J.D., DiCorleto P.E. Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ. Res. 2010, 106:902-910.
28. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009, 27:669-692.
29. Swirski F.K., Pittet M.J., Kircher M.F., Aikawa E., Jaffer F.A., Libby P., Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl. Acad. Sci. USA 2006, 103:10340-10345.
30. Peng Y., Latchman Y., Elkon K.B. Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J. Immunol. 2009, 182:2777-2785.
31. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
32. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
33. Hanninen A., Jaakkola I., Salmi M., Simell O., Jalkanen S. Ly-6C regulates endothelial adhesion and homing of CD8(+) T cells by activating integrin-dependent adhesion pathways. Proc. Natl. Acad. Sci. USA 1997, 94:6898-6903.
34. Niessner A., Weyand C.M. Dendritic cells in atherosclerotic disease. Clin. Immunol. 2009.
35. Cushing S.D., Fogelman A.M. Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. Arterioscler. Thromb. 1992, 12:78-82.
36. Sozzani S., Zhou D., Locati M., Bernasconi S., Luini W., Mantovani A., O'Flaherty J.T. Stimulating properties of 5-oxo-eicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3. J. Immunol. 1996, 157:4664-4671.
37. Potula H.S., Wang D., Quyen D.V., Singh N.K., Kundumani-Sridharan V., Karpurapu M., Park E.A., Glasgow W.C., Rao G.N. Src-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. J. Biol. Chem. 2009, 284:31142-31155.
38. Sears D.D., Miles P.D., Chapman J., Ofrecio J.M., Almazan F., Thapar D., Miller Y.I. 12/15-Lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009, 4:e7250.
39. Dioszeghy V., Rosas M., Maskrey B.H., Colmont C., Topley N., Chaitidis P., Kuhn H., Jones S.A., Taylor P.R., O'Donnell V.B. 12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J. Immunol. 2008, 181:6514-6524.
40. Chakrabarti S.K., Cole B.K., Wen Y., Keller S.R., Nadler J.L. 12/15-Lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 2009, 17:1657-1663.
41. Li S.L., Dwarakanath R.S., Cai Q., Lanting L., Natarajan R. Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J. Lipid. Res. 2005, 46:220-229.
42. Pacheco P., Vieira-de-Abreu A., Gomes R.N., Barbosa-Lima G., Wermelinger L.B., Maya-Monteiro C.M., Silva A.R., Bozza M.T., Castro-Faria-Neto H.C., Bandeira-Melo C., Bozza P.T. Monocyte chemoattractant protein-1/CC chemokine ligand 2 controls microtubule-driven biogenesis and leukotriene B4-synthesizing function of macrophage lipid bodies elicited by innate immune response. J. Immunol. 2007, 179:8500-8508.
43. Bonventre J.V., Huang Z., Taheri M.R., O'Leary E., Li E., Moskowitz M.A., Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390:622-625.
44. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., Komagata Y., Maki K., Ikuta K., Ouchi Y., Miyazaki J., Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997, 390:618-622.
45. Luo M., Jones S.M., Peters-Golden M., Brock T.G. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc. Natl. Acad. Sci. USA 2003, 100:12165-12170.
46. Radmark O., Werz O., Steinhilber D., Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 2007, 32:332-341.